TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07812597: A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With O

Sponsor: Beijing QL Biopharmaceutical Co.,Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 210 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,573,600

Rescue Site Savings

+$4,349,200

Unlock Full NCT07812597 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07812597 Rescue Dossier →